← All trials
NCT05423080
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 3, 2022
- Primary completion
- Nov 25, 2022
- Completion date
- Nov 25, 2022
- First posted
- Jun 21, 2022
- Last posted
- Dec 9, 2022
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Korea UniversityLead sponsor
- Korea UniversityOverall official - principal investigator
- Korea UniversityReponsible party - principal investigator
- Hana Pharmaceutical Co., LtdCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.